IL-27 |
|
Vaxjo ID |
278 |
|
Vaccine Adjuvant Name |
IL-27 |
|
Alternative Names |
Interleukin-27 |
|
Adjuvant VO ID |
VO_0005630
|
|
Description |
IL-27 is a heterodimeric cytokine composed of EBI3 and p28 subunits. It has dual roles: anti-inflammatory and pro-inflammatory, and is used here as a gene therapy agent delivered by AAV vector to modulate immune responses, deplete Tregs, and enhance tumor immunity |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
Cytokine heterodimer (EBI3 + p28), signals through IL-27R (WSX-1 + gp130) |
|
Molecular Weight |
Approx. 54 kDa |
|
Preparation |
Delivered by recombinant AAV vector, injected intramuscularly (i.m.) or intratumorally |
|
Dosage |
Typically 2 × 10¹¹ DRP/mouse, single dose used in mice |
|
Function |
We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model. |
|
Safety |
Well-tolerated in mice; no observed immune-related adverse events (IrAEs); low toxicity even at high systemic levels |
| References |
Seaver et al., 2022: Seaver K, Kourko O, Gee K, Greer PA, Basta S. IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model. Frontiers in immunology. 2022; 13; 884827. [PubMed: 35529885].
|
